• Explore /
  • Poster
  • / KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study.

KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study.

Abstract Poster

Authors

null

Hyun Cheol Chung

Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

Hyun Cheol Chung , Yung-Jue Bang , Charles S. Fuchs , Shukui Qin , Taroh Satoh , Kohei Shitara , Josep Tabernero , Eric Van Cutsem , Maria Alsina , Z. Alexander Cao , Xinqun Chen , Pooja Bhagia , Chie-Schin Shih , Yelena Yuriy Janjigian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03615326

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr TPS463)

Abstract #

TPS463

Poster Bd #

L7

Abstract Disclosures

Similar Posters

First Author: Yelena Yuriy Janjigian

First Author: Zev A. Wainberg

First Author: Yelena Y. Janjigian

First Author: Haeseong Park